Sequential plasma samples obtained from 16 individuals who seroconverted were tested for the presence of antibody to human immunodeficiency virus type 1 (HIV-1) by an antigen conjugate enzyme immunoassay (EIA) and a conventional antibody conjugate assay. In 11 of these individuals, the antigen conjugate assay detected antibody to HIV-1 2 to 11 days (mean, 5.5 days) earlier than the antibody conjugate assay. In 11 individuals, HIV-1 p24 antigen was detected a median of 6.5 days (range, 3 to 14 days) prior to positivity by the antigen conjugate EIA. Using class-specific probes, we determined the profiles of immunoglobulin M (IgM), IgG, and IgA antibodies for each individual and correlated these profiles with the ETA signals from both assays. In general, the appearance of IgM exhibited a peak at about 1 week postseroconversion, which was followed by gradually declining levels. Absorbance levels for IgG antibody, however, rose steadily and reached a plateau after 3 to 5 weeks. The levels of IgA were generally low and variable. In contrast to the progressive increase in ETA absorbance observed by the antibody conjugate assay, the antigen conjugate assay displayed a rapid early rise in absorbance which generally coincided with the transient expression of IgM antibody. The subsequent gradual increase coincided with rising levels of IgG. Because the configuration of the antigen conjugate ETA allows for an increased sensitivity for IgM compared with that for other classes of immunoglobulins, these results suggest that earlier detection of antibody to HIV-1 is due to the detection of IgM antibody during the early phase of seroconversion.
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The time of appearance and prevalence of antibodies other than immunoglobulin G (IgG) during seroconversion following human immunodeficiency virus (HIV) infection are still unclear. Various reports have indicated that from 50 to 100% of specimens contain IgM antibodies during the early stages of seroconversion (1, 3, 5, 6) . The contribution of IgA antibodies to the early immune response to HIV type 1 (HIV-1) has received little attention in cases other than infections in infants (8, (11) (12) (13) immune deficiency and AIDS (7) . Therefore, it is becoming increasingly important to identify individuals infected with either virus. Although this report is focused on the detection of antibody to HIV-1 during seroconversion, the antigen conjugate EIA can also detect simultaneously antibody to HIV-2.
MATERIALS AND METHODS
Samples. One hundred eight plasma samples collected from 16 individuals prior to and during seroconversion to HIV-1 seropositivity were obtained from two plasma collection centers. The average time between donations was 4.8 days (range, 2 to 30 days). The donors were not deferred on the basis of reported risk factors or clinical findings obtained before donation. Thus, most if not all of these individuals had asymptomatic seroconversions. Serologic and virologic data for some of the specimens, which were obtained by a conventional antibody conjugate assay (HIVAB-1 ETA; 3A11; Abbott Laboratories) and a licensed polyclonal HIV antigen assay (HIVAG-1; Abbott), have been described previously (9) .
Serology. Plasma samples were tested for antibody to HIV-1 by using a conventional antibody conjugate assay and by the new antigen conjugate assay. The antibody conjugate HIVAB-1 EIA (3A11; Abbott) uses viral HIV-1 proteins on the solid phase and an anti-human IgG-horseradish peroxidase enzyme conjugate to detect immunoglobulins bound to the solid phase (Fig. 1) . The HIV-1-HIV-2 antigen conjugate EIA uses a different format (Fig. 1) by adding 1 N H2SO4, and theA490 was measured. The cutoff of the assay is 0.1 optical density (OD) unit plus the mean absorbance value of the negative control. A sample is considered positive if the sample/cutoff ratio is 1.0 or greater. The sensitivity and specificity of the assay in various patient populations have been described previously (14, 15) .
For the detection of IgG, IgA, and IgM antibodies, we used class-specific probes in a microtiter plate assay. We do not have evidence that antibodies to particular HIV proteins appear earlier than other antibodies during seroconversion. Instead, we believe that the first type of antibody detected (anti-p41, anti-p24, other) is a function of the sensitivity of the assay being used. Because the signal obtained by the antigen conjugate EIA during seroconversion is derived primarily from antibody to gp4l (data not shown), we used only rp4l (containing 42 amino acids from the carboxy end of the HIV-1 p120 protein and 185 amino acids from the HIV-1 p41 protein) to coat the microtiter plates (Dynatech Laboratories, Chantilly, Va.). Plates were coated with recombinant antigen at 1 ,ug/ml for 2 h in 0.1 M 3-(cyclohexylamino)-lpropanesulfonic acid buffer (pH 11.0) and were then blocked with 5% nonfat dry milk in 10 mM Tris (pH 8.0)-0.15 M NaCl-0.05% Tween 20 (TBST) for 60 min. Five-microliter portions of sample diluted in 250 ,l of 5% milk-TBST were added to each well, and the plates were incubated for 2 h at room temperature. After washing eight times with 0.5% miik-TBST, 200 ,ul of biotinylated goat anti-human IgG (B-1518; Sigma, St. Louis, Mo.), anti-IgA (B-5893; Sigma), or anti-human IgM (B-2641; Sigma) diluted 1:20,000 in 5% milk-TBST was added and the solution was incubated for 1 h at room temperature. After eight washes with 0.5% milk-TBST, 175 pJ of streptavidin-horseradish peroxidase (14-30-00; Kirkegaard and Perry Laboratories, Gaithersburg, Md.) at 2 ,ug/ml in 5% milk-TBST was added, and the mixture was incubated for 15 min at room temperature. The plates were washed eight more times as described above and briefly rinsed with distilled water, and the o-phenylenediamine-2 HCI substrate was added for 2 min before stopping the reaction with 1 N H2SO4. A490 values were measured. Results are given as corrected OD units (OD of the sample -OD of the negative control) and reflect the means of triplicate measurements. A sample was considered positive when it had a corrected OD equal to or greater than 0.05.
To determine whether the OD values obtained by the class-specific antibody assay reflected the relative levels of IgM, IgG, and IgA antibodies, we determined the specific activities of each probe. Microtiter wells were coated in triplicate with highly purified human IgM, IgG, or IgA (31145, 31146, and 31148, respectively; Pierce, Rockford, Ill.) at a concentration of 0.125 ,ug/ml (corresponding to approximately 0.02 ,ug of immunoglobulin per assay). Serial dilutions indicated that this protein concentration allows the greatest discrimination of specific activity for the probes. Separate, duplicate plates were stained with colloidal gold (Bio-Rad Laboratories, Richmond, Calif.) to verify that similar amounts of each immunoglobulin were bound to the microtiter wells. The probes were then allowed to react with their respective target immunoglobulins, and the microtiter assay was completed as described above. The specific activity of each probe was calculated as the absorbance units per microgram of target immunoglobulin. For the anti-IgG, -IgM, and -IgA probes, these values were 37.0, 38.5, and 23.5 absorbance units per ,ug, respectively. Thus, the specific activities of the anti-IgG and anti-IgM probes were similar, while the specific activity of the anti-IgA probe was approximately 60 to 70% of that of the other two probes. These relative specific activities were reproducible at other concentrations of target immunoglobulins (data not shown).
We also determined that the biotinylated anti-IgA, antiIgM, and anti-IgG probes did not cross-react with other classes of antibodies (data not shown).
The E. coli assay was identical to the class-specific antibody assay, except that E. coli lysate at 1 ,ug/ml was coated on the microplates. Antibody class composition of seroconversion samples. To determine the class of HIV-1 antibody present during seroconversion, we used anti-class-specific antibodies as probes. The antibodies present in each sample from 16 individuals during seroconversion were captured on microtiter plates coated with recombinant, purified rp4l antigen and then detected with anti-mu-, anti-gamma-, and anti-alpha-specific probes as described in Materials and Methods.
IgM antibodies to rp4l were detected in all the samples that were positive by the antigen conjugate EIA at the early stage of seroconversion. Sequential samples from 15 of the 16 persons contained transient levels of IgM antibodies. In most individuals, a peak of IgM antibody was observed an average of 5.5 days (range, 2 to 12 days) after detection of the first antibody-positive samples by the antigen conjugate assay. One series of specimens (SV71) had increasing levels of IgM antibody spanning the 11 days over which samples were obtained.
Low levels of IgG antibodies were detected in 13 of 15 samples that were negative by the antibody conjugate EIA yet positive by the antigen conjugate assay. The remaining samples (C1066, day 5; SV21, day 1) were negative for IgG. In contrast to the transient nature of the IgM antibodies, the levels of IgG antibodies increased with time in all seroconversions.
IgA antibodies were detected in 12 individuals. Unlike the patterns observed for IgM and IgG antibodies, the levels of IgA antibodies were more variable and appeared to fluctuate at generally low levels.
To establish that the OD values obtained by each antibody class-specific assay reflected the presence of specific anti-HIV antibodies, we tested 15 series of samples (all except series 2425) for reactivity against E. coli lysate and for the presence of rheumatoid factor. Low-level reactivity to E. coli lysate was found in 14 samples from only two individuals (H831 and AY). The values obtained for the assay did not change significantly during seroconversion in these two series (data not shown), so that no correlation could be established between E. coli-specific reactivity and HIV-1-specific IgG, IgM, or IgA positivity. Rheumatoid factor was not detected in any of the samples analyzed in this study and thus did not contribute to the EIA signal obtained from these samples.
DISCUSSION
The antigen conjugate EIA reduces the "window" period for serologic detection of seroconversion to HIV-1 by detecting positive samples earlier than conventional assays which use anti-human IgG-enzyme conjugates. In 11 of 16 individuals, samples were positive for HIV-1 antibody 2 to 11 days (mean, 5.5 days) prior to being positive by the antibody conjugate EIA. We obtained similar results for samples from an additional five individuals who seroconverted after HIV-1 infection. In three of the individuals, the antigen conjugate EIA detected HIV antibody 4 to 14 days (mean, 6.5 days) earlier than the antibody conjugate assay (data not shown). Therefore, the antigen conjugate assay detected the presence of HIV-1 antibody approximately 1 week before the antibody conjugate assay.
We investigated the time of appearance and prevalence of antibodies other than IgG at the early stages of seroconversion to HIV-1. Because the antibody class-specific microtiter assay was optimized for sensitivity and was not constrained by specificity issues, as is the case for commercial screening assays, there was detectable antibody in many samples prior to positivity for HIV-1 by either ETA. In most individuals, IgA antibody did not seem to contribute significantly to the early signal obtained by the antigen conjugate assay. Indeed, samples from 4 of 16 individuals did not contain detectable IgA at all. Even doubling of the corrected OD, to account for the lower specific activity of the anti-IgA probe, would not change this observation. Although some investigators have detected IgM in only 50% of early seroconversion samples (6), it appears that IgM is present in most if not all individuals at the early stages of the immune response to HIV infection (1, 3, 9) . In our study, IgM antibody was transiently present in all individuals, which is in agreement with the obligatory role of IgM in the initial antibody response of B cells (10) . The levels of IgM rose and declined over a 2-to 3-week period, reaching a peak at about 6 days after initial positivity by the antigen conjugate assay. Our results confirm the observations of (4) . This further suggests that the antigen conjugate EIA detects mostly IgM in the samples that are positive by the antigen conjugate EIA but that are still negative by the antibody conjugate EIA. Therefore, the earlier detection of seroconversion appears to be due to the greater sensitivity of the antigen conjugate assay to IgM antibody.
In 11 of 16 individuals (68%), the presence of HIV-1 p24 antigen was detected a mean of 6.5 days prior to positivity by the antigen conjugate EIA. Therefore, in general, the order of appearance of serological markers of HIV-1 infection detectable with current EIA technology appears to be as follows: for about 1 week, the presence of HIV-1 p24 antigen, then, for about 1 week, the presence of IgM to HIV-1 and then the continuous presence of IgG to HIV-1.
In summary, the antigen conjugate EIA effectively detects seroconversion to HIV-1 earlier than a current antibody conjugate EIA does. This increased sensitivity correlates with the presence of IgM antibody detected in all individuals who seroconverted.
